The Food and Drug Administration is investigating serious adverse events involving Limbrel, a capsule being marketed as a medical food to manage the metabolic processes associated with osteoarthritis. Health care providers who know their patients are taking the product should advise them to stop taking it immediately, FDA said. While a range of adverse events have been reported, two serious and potentially life-threatening medical conditions are among them: drug-induced liver injury and hypersensitivity pneumonitis. For more information, see the FDA safety alert.

Related News Articles

Headline
AHA Feb. 15 reiterated its support for the Future Advancement of Academic Nursing Act, recently reintroduced by Sen. Jeff Merkley, D-Ore., and Rep. Lauren…
Headline
Ellen Brzytwa, R.N., a trustee at the Cleveland Clinic, discusses her mission to recruit more nurses to hospital board positions. LISTEN NOW
Headline
Fisher-Titus Medical Center in Norwalk, Ohio, addressed its nursing workforce gap by recruiting international nurses and working to create a welcoming and…
Headline
The Centers for Medicare & Medicaid Services Nov. 15 finalized public reporting requirements for skilled nursing facilities participating in the…
Chairperson's File
On today’s episode, I talk with Mary Beth Kingston, executive vice president and chief nursing officer at Advocate Health. She also is a past president of the…
Headline
The Centers for Medicare & Medicaid Services’ proposal to implement mandatory nurse staffing levels “would have serious, negative, unintended consequences…